Safety and Traceability in the Wake of GE Healthcare's FBS Recall- An interview with Rosemary Versteegen

Gerald Clarke

When GE Healthcare recently withdrew their Fetal Bovine Serum (FBS) products due to non-conformancies, it highlighted the real need for product safety and traceability practices in the field. Pharma IQ spoke to Rosemary Versteegen, CEO of the International Serum Industry Association about this case and what the industry can learn from it. [inlinead]
To continue reading this story get free access